Mecasermin / Recombinant Human IGF-1 (Increlex, rhIGF-1) — Research Compounds Library | RetatrutideCompare
Recombinant human IGF-1. FDA-approved for severe primary IGF-1 deficiency. Hypoglycemia is the main dose-limiting adverse event.
Recombinant human IGF-1. FDA-approved for severe primary IGF-1 deficiency. Hypoglycemia is the main dose-limiting adverse event.